Arpit Kashyap1, Chenghui Li. 1. Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Abstract
OBJECTIVE: To describe the trend in atrial fibrillation (AF) treatment strategies in newly diagnosed AF patients between 1999 and 2008. METHODS: The study was a retrospective cohort study of commercial health plans claims data. Newly diagnosed adult AF patients with ≥1 claim for an AF-related intervention within 12 months of diagnosis were identified. Based on initial treatment, patients were classified into pharmacotherapy or nonpharmacotherapy groups. Pharmacotherapy group was subcategorized into rate-control or rhythm-control groups. Linear regression to assess linear trend and multinomial logistic regression to evaluate factors associated with treatment choice were conducted. RESULTS: Three thousand ninety-four newly diagnosed AF patients were identified. Eighty percent of these patients were initiated on pharmacotherapy with the majority (84%) receiving rate-control medications only. Relative distribution of the 3 treatment groups remained similar over the study period. However, within the rate-control group, the use of beta blockers increased significantly (P < .001). Treatment with nonpharmacotherapy over rate-control medications was higher in males but lower in patients aged ≥80 (relative risk ratio [RRR]: 1.67, 95% confidence interval [CI]: 1.27-2.20 and RRR: 0.48, 95% CI: 0.30-0.77, respectively). Having stroke and congestive heart failure significantly affected the treatment choice between nonpharmacotherapy and rate-control medications. CONCLUSION: Medication therapy, especially rate-control strategies, remains the preferred initial therapy of choice.
OBJECTIVE: To describe the trend in atrial fibrillation (AF) treatment strategies in newly diagnosed AFpatients between 1999 and 2008. METHODS: The study was a retrospective cohort study of commercial health plans claims data. Newly diagnosed adult AFpatients with ≥1 claim for an AF-related intervention within 12 months of diagnosis were identified. Based on initial treatment, patients were classified into pharmacotherapy or nonpharmacotherapy groups. Pharmacotherapy group was subcategorized into rate-control or rhythm-control groups. Linear regression to assess linear trend and multinomial logistic regression to evaluate factors associated with treatment choice were conducted. RESULTS: Three thousand ninety-four newly diagnosed AFpatients were identified. Eighty percent of these patients were initiated on pharmacotherapy with the majority (84%) receiving rate-control medications only. Relative distribution of the 3 treatment groups remained similar over the study period. However, within the rate-control group, the use of beta blockers increased significantly (P < .001). Treatment with nonpharmacotherapy over rate-control medications was higher in males but lower in patients aged ≥80 (relative risk ratio [RRR]: 1.67, 95% confidence interval [CI]: 1.27-2.20 and RRR: 0.48, 95% CI: 0.30-0.77, respectively). Having stroke and congestive heart failure significantly affected the treatment choice between nonpharmacotherapy and rate-control medications. CONCLUSION: Medication therapy, especially rate-control strategies, remains the preferred initial therapy of choice.
Authors: Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann Journal: Eur Heart J Date: 2006-08 Impact factor: 29.983
Authors: Karin S Coyne; Clark Paramore; Susan Grandy; Marco Mercader; Matthew Reynolds; Peter Zimetbaum Journal: Value Health Date: 2006 Sep-Oct Impact factor: 5.725
Authors: Edward P Gerstenfeld; David Callans; Sanjay Dixit; David Lin; Joshua Cooper; Andrea M Russo; Ralph Verdino; Mark Weiner; Erica Zado; Francis E Marchlinski Journal: J Cardiovasc Electrophysiol Date: 2006-11-01
Authors: Hakan Oral; Christoph Scharf; Aman Chugh; Burr Hall; Peter Cheung; Eric Good; Srikar Veerareddy; Frank Pelosi; Fred Morady Journal: Circulation Date: 2003-10-13 Impact factor: 29.690
Authors: Nancy M Allen LaPointe; Yuliya Lokhnygina; Gillian D Sanders; Eric D Peterson; Sana M Al-Khatib Journal: Am Heart J Date: 2013-09-24 Impact factor: 4.749
Authors: Nancy M Allen LaPointe; Yuliya Lokhnygina; Jacqueline Rimmler; Gillian D Sanders; Eric D Peterson; Sana M Al-Khatib Journal: J Atr Fibrillation Date: 2014-06-30